{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:12:02Z","timestamp":1788797522880,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T00:00:00Z","timestamp":1436400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/Background:<\/jats:title>\n                    <jats:p>\n                      Isoniazid (INH) is one of the effective antituberculosis (TB) drugs used for TB treatment. However, most of the drug-resistant\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) clinical strains are resistant to INH, a first-line antituberculous drug. Certain metabolic enzymes such as adenosylhomocysteinase (Rv3248c), universal stress protein (Rv2623), nicotinamide adenine dinucleotide (reduced)-dependent enoyl-acyl carrier protein reductase (Rv1484), oxidoreductase (Rv2971), dihydrofolate reductase (Rv2763c), pyrroline-5-carboxylate dehydrogenase (Rv1187) have been identified to bind INH\u2013nicotinamide adenine dinucleotide (INH\u2013NAD) and INH\u2013nicotinamide adenine dinucleotide phosphate adducts coupled to Sepharose resin. These enzymes are reported to be involved in many important biochemical processes of MTB, including cysteine and methionine metabolism, mycobacterial growth regulation, mycolic acid biosynthesis, detoxification of toxic metabolites, folate biosynthesis, etc. The truncated INH\u2013nicotinamide adenine dinucleotide (oxidized) adduct, 4-isonicotinoylnicotinamide, isolated from urine samples of human TB patients treated with INH therapy is proposed to have antimycobacterial activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To understand the mechanism of interaction of the truncated INH\u2013NAD adduct, binding energy studies were carried out on the aforementioned six enzymes with known three-dimensional structures using AutoDock4.2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In silico docking analysis of these MTB enzymes with the truncated INH\u2013NAD adduct showed favorable binding interactions with docking energies ranging from \u22125.29 to \u22127.07kcal\/mol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Thus, in silico docking study revealed that the INH\u2013NAD adduct, which is generated\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      after INH activation, may undergo spontaneous hydrolysis to form the truncated INH\u2013NAD adduct and further binds and inhibits multiple enzymes of MTB, in addition to InhA, confirming that INH is an effective anti-TB drug acting at multiple enzymes. Further analysis of amino acid residues in the active site of INH\u2013NAD-binding proteins showed the probable presence of catalytic triad in four enzymes possibly involved in INH binding to the enzyme.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijmyco.2015.06.006","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T21:53:47Z","timestamp":1436997227000},"page":"276-283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Study of mechanism of interaction of truncated isoniazid\u2013nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach"],"prefix":"10.4103","volume":"4","author":[{"given":"Lingaraja","family":"Jena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita","family":"Waghmare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar C.","family":"Harinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-3-20260907","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jama.1995.03520270054031","article-title":"Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic","volume":"273","author":"Raviglione","year":"1995","journal-title":"JAMA"},{"key":"R3-3-20260907","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3201\/eid1303.061400","article-title":"Worldwide emergence of extensively drug-resistant tuberculosis","volume":"13","author":"Shah","year":"2007","journal-title":"Emerg. Infect. Dis"},{"key":"R4-3-20260907","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1099\/00221287-146-2-289","article-title":"InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II","volume":"146","author":"Marrakchi","year":"2000","journal-title":"Microbiology"},{"key":"R6-3-20260907","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/AAC.27.3.399","article-title":"Peroxidase-mediated oxidation of isoniazid","volume":"27","author":"Shoeb","year":"1985","journal-title":"Antimicrob. Agents Chemother"},{"key":"R7-3-20260907","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1128\/AAC.48.8.3006-3009.2004","article-title":"Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis","volume":"48","author":"Timmins","year":"2004","journal-title":"Antimicrob. Agents Chemother"},{"key":"R8-3-20260907","doi-asserted-by":"crossref","first-page":"13881","DOI":"10.1073\/pnas.2235848100","article-title":"The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance","volume":"100","author":"Rawat","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"R9-3-20260907","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1021\/ja00122a038","article-title":"Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis","volume":"117","author":"Johnsson","year":"1995","journal-title":"J. Am. Chem. Soc"},{"key":"R10-3-20260907","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4236\/ojmm.2012.21004","article-title":"Review: the molecular basis of resistance in Mycobaterium tuberculosis","volume":"2","author":"Santos","year":"2012","journal-title":"Open J. Med. Microbiol"},{"key":"R11-3-20260907","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.2174\/15672050113109990203","article-title":"Isoniazid: an update on the multiple mechanisms for a singular action","volume":"20","author":"Bernardes-G\u00e9nisson","year":"2013","journal-title":"Curr. Med. Chem"},{"key":"R12-3-20260907","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1110\/ps.041163505","article-title":"Binding of the antitubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis","volume":"14","author":"Sandy","year":"2005","journal-title":"Protein Sci"},{"key":"R13-3-20260907","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jmgm.2008.09.006","article-title":"Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach","volume":"27","author":"Stigliani","year":"2008","journal-title":"J. Mol. Graph. Model"},{"key":"R14-3-20260907","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/AAC.05486-11","article-title":"A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct","volume":"56","author":"Mahapatra","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"key":"R15-3-20260907","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1016\/j.ejmech.2010.07.016","article-title":"Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents","volume":"45","author":"Delaine","year":"2010","journal-title":"Eur. J. Med. Chem"},{"key":"R16-3-20260907","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijmyco.2014.08.003","article-title":"Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug","volume":"3","author":"Jena","year":"2014","journal-title":"Int. J. Mycobacteriol"},{"key":"R17-3-20260907","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/JB.181.4.1343-1347.1999","article-title":"Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance","volume":"181","author":"Payton","year":"1999","journal-title":"J. Bacteriol"},{"key":"R18-3-20260907","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1099\/00221287-147-12-3295","article-title":"Evidence towards the role of arylamine N acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis","volume":"147","author":"Payton","year":"2001","journal-title":"Microbiology"},{"key":"R19-3-20260907","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1021\/ja002674f","article-title":"Oxidation of isoniazid by manganese and Mycobacterium tuberculosis catalase peroxidase yields a new mechanism of activation","volume":"123","author":"Bodiguel","year":"2001","journal-title":"J. Am. Chem. Soc"},{"key":"R20-3-20260907","doi-asserted-by":"crossref","first-page":"13947","DOI":"10.1021\/bi061874m","article-title":"Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis","volume":"45","author":"Argyrou","year":"2006","journal-title":"Biochemistry"},{"key":"R22-3-20260907","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1107\/S0907444904011679","article-title":"PRODRG: a tool for high-throughput crystallography of protein-ligand complexes","volume":"60","author":"Sch\u00fcttelkopf","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"R23-3-20260907","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem"},{"key":"R24-3-20260907","doi-asserted-by":"crossref","first-page":"e1000460","DOI":"10.1371\/journal.ppat.1000460","article-title":"Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATP-binding: requirement for establishing chronic persistent infection","volume":"5","author":"Drumm","year":"2009","journal-title":"PLoS Pathog"},{"key":"R25-3-20260907","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-4939-2343-4_27","article-title":"Scoring functions for AutoDock","volume":"1273","author":"Hill","year":"2015","journal-title":"Methods Mol. Biol"},{"key":"R26-3-20260907","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1107\/S2053230X14007158","article-title":"A structural characterization of the isoniazid Mycobacterium tuberculosis drug target, Rv2971, in its unliganded form","volume":"70","author":"Shahine","year":"2014","journal-title":"Acta Crystallogr. F Struct. Biol. Commun"},{"key":"R27-3-20260907","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1155\/2013\/309816","article-title":"Mycobacterial dormancy regulon protein Rv2623 as a novel biomarker for the diagnosis of latent and active tuberculous meningitis","volume":"35","author":"Jain","year":"2013","journal-title":"Dis. Markers"},{"key":"R28-3-20260907","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/srep02264","article-title":"Regulation of homocysteine metabolism by Mycobacterium tuberculosis Sadenosylhomocysteine hydrolase","volume":"3","author":"Singhal","year":"2013","journal-title":"Sci. Rep"},{"key":"R29-3-20260907","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1126\/science.279.5347.98","article-title":"Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis","volume":"279","author":"Rozwarski","year":"1998","journal-title":"Science"},{"key":"R30-3-20260907","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.46.7.2137-2144.2002","article-title":"Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis","volume":"46","author":"Nguyen","year":"2002","journal-title":"Antimicrob. Agents Chemother"},{"key":"R31-3-20260907","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1107\/S1399004713034391","article-title":"Characterization of the proline-utilization pathway in Mycobacterium tuberculosis through structural and functional studies","volume":"70","author":"Lagautriere","year":"2014","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"R32-3-20260907","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jmb.2004.01.059","article-title":"Structural and catalytic diversity in the two family 11 aldo\u2013keto reductases","volume":"337","author":"Ehrensberger","year":"2004","journal-title":"J. Mol. Biol"},{"key":"R33-3-20260907","doi-asserted-by":"crossref","first-page":"15582","DOI":"10.1074\/jbc.274.22.15582","article-title":"Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate","volume":"274","author":"Rozwarski","year":"1999","journal-title":"J. Biol. Chem"},{"key":"R34-3-20260907","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijbiomac.2010.01.011","article-title":"Recognition of active and inactive catalytic triads: a template based approach","volume":"46","author":"Gupta","year":"2010","journal-title":"Int. J. Biol. Macromol"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553115001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553115001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01929415-201504040-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:00:35Z","timestamp":1788796835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01929415-201504040-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijmyco.2015.06.006","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}